HM15912 Active

Phase 2

Hanmi Pharmaceutical Company Limited

HM15912 Active is one of 12 therapeutic programs targeting Short Bowel Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Short Bowel SyndromeRecruiting

Short Bowel SyndromePhase 2

Recruiting

Competition

Competitive Landscape

13 competitors in Short Bowel Syndrome

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Victoza

Glepaglutide

5 4

Apraglutide

VVectivBio AG

Phase 3

2 5

PJ009

CChongqing Peg-Bio Biopharm Co., Ltd.

Phase 3

1 6

Celexa

AbbVie

Preclinical

1 7

Mytesi

NNapo Pharmaceuticals, Inc.

Phase 1

1 8

Genotropin

Glutamine

1 10

HM15912 Active

Hanmi Pharmaceutical Company Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Short Bowel Syndrome

NCT04775706

Clinical

Trials by Indication[1]

Short Bowel Syndrome1 trial

A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT04775706·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HM15912 Active. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for HM15912 Active. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hanmi Pharmaceutical Company Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Hanmi Pharmaceutical Company Limited

HM15912 Active

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Short Bowel Syndrome1 trial

References

Drug Info

Quick Facts

Related News